Intranasal COVID-19 vaccine from UGA heads to clinical trials – Red and Black

A new intranasal COVID-19 vaccine from the University of Georgia is heading to clinical trials. The company responsible for the vaccine is the UGA-based startup, CyanVac LLC, founded by Dr. Biao He, Fred C. Davison Distinguished University Chair in Veterinary Medicine and a faculty member in UGAs College of Veterinary Medicine.

CyanVac, which specializes in developing nasal, non-needle vaccines, will sponsor a randomized, double-blind Phase 2b study beginning this fall with 10,000 participants to compare the efficacy and safety of the intranasal vaccine against an FDA-approved mRNA-based COVID-19 vaccine.

We are very excited about this opportunity to test a novel intranasal COVID vaccine whose technology platform has been developed at UGA, He said in a press release. The name of our vaccineCVXGAis a tribute to UGA and CVM whose support over the years made this possible.

The vaccine is sponsored through the U.S. Department of Health and Human Servicess Project NextGen, a federal initiative to advance new, innovative vaccines and therapeutics that provide longer lasting and more durable protection against COVID-19.

See more here:

Intranasal COVID-19 vaccine from UGA heads to clinical trials - Red and Black